dotMD.com
✓ Translated by DotMD AI Clinical Council Source: Lancet (London, England) • Meta-Analysis
Verify Primary Source: NIH PubMed PMID #28390695
Plain-English Research Story • 8th-Grade Reading Level

New Insights on Achieved blood pressure and heart and blood vessel outcomes in high-risk: What a 8,407-Participant Study Found

Mean achieved SBP less than 120 mm Hg during treatment was associated with increased risk of heart and blood vessel outcomes except for heart attack and stroke.

Original Paper Title: “Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials” (Lancet (London, England), 2017-06-03)

Elena Rostova (AI Quant) Rigor Score
99 / 100
Sample Size (Participants)
N = 8,407
Evidence Classification
Meta-Analysis
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • The Bottom-Line Finding: Mean achieved SBP less than 120 mm Hg during treatment was associated with increased risk of heart and blood vessel outcomes except for heart attack and stroke.
  • Who Was Studied: Meta-Analysis published in Lancet (London, England) following 8,407 real-world participants.
  • Strength of the Evidence: Earned a 99/100 Study Rigor Score based on trial design, sample size, and peer-reviewed controls.
  • Smart Next Step: Share this plain-English summary with your doctor or pharmacist before starting, stopping, or changing any treatment.
The Full Story in Plain English

What the Study Found (In Plain English)

Why This Matters to You

Studies have challenged the appropriateness of accepted blood pressure targets. When you or someone you love is weighing a treatment choice, dense medical journals can feel overwhelming. Yet the core question behind this research is one that everyday patients ask all the time: does this approach actually help you feel or function better—and is it safe?

How the Study Worked

To find out, researchers writing in Lancet (London, England) conducted a meta-analysis evaluating 8,407 real-world participants. Rather than relying on guesswork or anecdotal reports, the research team tracked measurable health outcomes and day-to-day side effects under controlled clinical conditions.

What the Study Found in Plain English

Mean achieved SBP less than 120 mm Hg during treatment was associated with increased risk of heart and blood vessel outcomes except for heart attack and stroke. Similar patterns were observed for DBP less than 70 mm Hg, plus increased risk for heart attack and hospital admission for heart failure. Instead of leaving patients in the dark, these results give you and your doctor concrete data you can weigh together.

The Catch: What to Keep in Mind

Even strong medical studies have limits. Every person's body handles medicines, supplements, and lifestyle changes differently depending on age, kidney and liver health, and other prescriptions in the medicine cabinet. What worked on average in a clinical study may still need a personalized dose or a different option for you.

Bottom Line: Your Next Step

Bring this summary to your next doctor or pharmacist visit. Ask: "Based on my health history and current medications, does this research apply to me?" You can also click the formal study link below to inspect the original peer-reviewed paper directly.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Published in Lancet (London, England) (2017-06-03) • Study Design: Meta-Analysis • Participants: N = 8,407 • Biostatistical Rigor Score: 99/100. Primary Takeaway: Mean achieved SBP less than 120 mm Hg during treatment was associated with increased risk of heart and blood vessel outcomes except for heart attack and stroke.

Study Limitations & Caveats Before You Act

While this meta-analysis scored 99/100 for research quality, clinical trials follow strict rules that may not match every patient's daily life. Always check with your doctor or pharmacist for drug interactions and personal risk factors before acting on new research.

Formal Peer-Reviewed Study Reference
“Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials”
Published in Lancet (London, England) (2017-06-03) • PMID/ID: 28390695
Read Formal Study

Related DotMD Clinical Hubs & Price Ledgers

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 28390695: New Insights on Achieved blood pressure and heart and blood vessel outcomes in high-risk: What a 8,407-Participant Study Found

3 of 3 Free Questions Remaining